- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Yoruba
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Proin
Baofa Yu, M.D. dux Medicus in Sinis, Professor Adjunctus in Universitate Texas (El Paso) (2016) et Professor in Universitate Scientiarum Sanitatis occidentalis (2016) . Deduxit a Peking Unione Medical Collegium (Peking Unionis Medical College) in MCMLXXXVIII. Fuit sodalis post doctoralem UCSD ab anno 1990 ad 1991, Salk ab 1992 ad 1993, Professor Adjunctus, UCSD ab 1994 ad 1998. In Civitatibus Foederatis maxime versatus est in investigatione pharmaci pharmaci cancri traditio et tumorem biologiam hypotheticam. Novam notionem invenit usus tumoris textus sicut systematis emissio sustinentis anticancri medicamentorum et curationis methodum alveus emissio sustinentis, quae valorem applicationem clinicum habet, etiam ultro-Minimum incisio chemoimmunotherapy intratumoralis (UMIPIC). In 1998, in Sinas rediit et Shandong Baofa Instituti Research condidit et Taimei Baofa Cancri Hospitale in Dongping rustica area cum obsidione technologica, et praeses Shandong Baofa Cancri Co., LTD functus est, et postea Jinan Baofa Cancer Hospitalis constituit (2004). Dongping Baofa Hospitalis Generalis (2011), Beijing Baofa Cancri Hospitalis (2013) et Oncologiae Immuno Systems, Inc. Hoc UMIPIC tutum est, facile ad operandum, et cum bono solido tumore producitur. Hodie haec therapia accipitur "Clineal Operation Guidelines for Interventional Treatment of Advanced Pancreatic Cancer" (Trial) (7th edition), coniunctim a Seres Anti-Cancer Associationis, Nationalis Fuscae Medical Research Centrum pro Radiologia et Therapy, ac Medicinae Interventional Nationalis Innovationis Foedus, Acta Radiologiae Fuscae, tomo XLIII, numero XIX, 2024, MDCXXXVI.
Plus quam 60 tabulas de hac therapia in Natura: Relatione Scientifica, Acta Cancri, J Basic Clin Pharma, J Inmunologico Sci, Acta Iaponica Gastroenterologiae et Hepatologiae, Novellae Accessiones in Cancro Study, Acta Scientiarum Investigationis, Nov Res Sci, Acta carcinomatis Hepatocellularis, pulmonis, Cancri, Acta livoris et therapiae, Therapy, Sinica, Acta Inquisitionis et Therapiae Arca, Proc.Natl.Acad.Sci.USA, Pancreas et aliae ephemerides et multae chartae postes in AACR et ASCO conventu participaverunt.
Maior contributio nostra est quod therapiae sustentatae commoda chemotherapyae et immunotherapiae integrant, et primum duo coniuncta et applicata ad therapiam intratumoralem per interventum. Curationem localem et globalem integrat, et retrahitur ac tempus actionis medicamentorum auget per sustentationem medicamentorum intra tumorem emissionem, qui non solum effectus anticancer localis medicamentorum chemotherapyarum, sed etiam munus systemicum immunotherapy considerat, ita ut defectus aliarum therapiarum componens novas ideas et accessus ad curationem cancri, praesertim medii et provectae tumores, praecipue ad tumorem reducendum et tumores recurrentes, praesertim ad minuendos tumores et inhibendo tumores maximi ponderis UMPIC Lorem commodum est utendi tumore antigeno fonte et vaccino autologo, quod etiam congruit cum trend evolutionis medicinae Personalised. Et applicata ad clinic, conjuncta cum chemotherapy medicamentis ad sustentationem emissionem curationis cancri pancreatici primi umbilici, inducens effectum distali, cuius essentia est immunem responsionem inducere, T-cellularum CD4, CD8, DC, T et NK cellularum, et B-cellularum autoantibodium tumorem relatas: elementorum ad P53, P16, IMP1, Koc, Zeta; oncogenes, hoc primum reperire T et B involvit immune responsionis ac functionibus distali effectus clinicis et haec cura deligitur "Cinical Operation Guidelines pro Interventional Treatment of Advanced Pancreatic Cancer" (Trial) (7th edition) coniunctim a Sinensi Consociatione Anti-Cancer, Centro Nationali Nationali Nationali Nationali Nationali Nationali Nationali Nationali Nationali curatione Interventionis Curatio Provectus Pancreatic Cancer (7th edition) editam inter Anti-Cancer Consociationis Sinensium, Interventus Nationalis clinicae Medicae Investigationis ac Radiologiae et Therapy Medicae interventus Jo. de Radiologia Fuscae, volumen 43, numero 19, 2024, 1636-1648.
Notae:
| Annus | Articulus Titulus | Publication |
| 2015 | Effectus therapeuticus effectus in provectae cancri pulmonis stadiis per ultra-minimam incisionem personalem intratumoralem hapten consecutus est. | Pulmo Cancer: target et Therapy, MMXV, VI 1-11 |
| 2015 | Tuens normalem ut cancer melius occideret | 2015 Auctores. Medicina Cancer edita a Johanne Wiley & Sons Ltd.1349-1403 |
| 2015 | Infirmitatibus et foveis utendi Muribus et caricibus in Cancro Chemoprevention Studies | Acta Cancri 2015;6(10): 1058-1065.doi: 10.7150/jca.12519 |
| 2015 | Consectetur altiore tempore superstes in carcinomate hepatocellulari provectus per ultra-minimum incisum personale chemoimmunotherapy intratumorale | Acta Societatis Hepatocellular Carcinoma 2015:2，1-12 |
| 2015 | Usus medicamentorum catatonicorum compositorum hapten ad augendam therapeuticam effectum in progressu Cancri pancreatici | Acta Livoris Research, Disorders & Therapy, 2015,1(3):013-23 |
| 2016 | Doctrina de Momento Mutationis Praeventionis a Curable Cancros et Tumores Benigni | Acta Cancri 2016; 7(4): 436-445. doi: 10.7150/jca.13832 |
| 2016 | Improved Overall Survival Benefit in Late Gradus Non-Small Cell Lung Cancer (NSCLC) per Ultra-Minimum Incisum Privatum Chemo Immunotherapy (UMIPIC) Therapy With and without Radiation Therapy Submit Manuscript | Acta Cancri Praeventionis & Current Research 2016, 4(2): 00116 |
| 2020 | A Novella Eclectica Accessio ad Cancrum Therapy cum Liquid Cultro & Immuno Therapy: UMIPIC, comprehendere potest multas Surgerys, Chemotherapy et Radiatio Therapy pro omnibus Stadiis Solidi Tumoris | Novitates in Cancro Study NACS.000590. 4(3).2020 |
| 2020 | Medicatum ab H2O2 Iniectio intratumoralis ad extracellularem Matrix inAutologum Coagulum ut medicamentum Depot convertens | Nova Investigatio in Scientiis NRS.000584. 4(2).2020 |
| 2020 | Cancer Therapy Liquid & Immuno Therapy: UMIPIC | Current Trends in Clinical & Medical Sciences ISSN:2689-4246 Published Date: March 20, 2020 |
| 2022 | Inflammatio tumoris acutus cum CD4/8+ et CD11+ augetur Long Survival Tempus in Provectio omnium tumorum solidorum per Ultra Minimum Incisum Privatum Chemoimmunotehrapy intratumorale | Acta Iaponicae Gastroenterologiae et Hepatologiae |
| 2022 | Inflammatio acuta cum expressione speciali CD11 & CD4 producit effectum abscopalem per Injectionem Chemotherapy medicamentum cum Hapten in Exemplar Animali. | Acta Scientiarum Immunologicarum |
| 2022 | A Novo Immuno Surgery Egrediente : Novus Eclectic Accessus Curatio Cancri cum Liquid Cultro & Immuno Therapy | Acta Academica Studiorum Engineering |
| 2022 | Inflammatio tumoris acutus cum CD4/8+ et CD11+ Prolonga effectus superstes inductus per Injectionem Injectionem Optimum Medicamenta Chemotherapy cum Hydralazine ut Hapten in Exemplar Animali. | Acta Iaponicae Gastroenterologiae et Hepatologiae |
| 2023 | Excita Cellulae immunes ab Hapten Consectetur Chemotherapy intratumoralis cum Penicillin Longa Pancreatica Cancer superstes. | Acta Cancri 2023; 14(8): 1282-1292 . |
| 2023 | Prosperum targeting in situ antigeni nuclei oncogenici per eventum inductum tumoris autoantibodies consociatae (iTAA） | naturae portfolio Scientific Reports volume 13, Article number: 9902 (2023) |
| 2023 | De Immunis Mutationibus Intratumoralibus Hapten Plus Chemotherapy Medicamenta EndometrialCancer inductae | Acta pharmacopolia Basic et Fusce pharmacy July 31,2023. DOI: 10.37532/0976-0113.14(S1).17 |
| 2023 | Cancer Immunotherapy Praeparatio et Immune Cellae Activatio per Hapten-Consectetur Chemotherapy in Primario Pulmonis Cancri | Acta Pharmacy Fusce et Fusce August 11, 2023. DOI: 10.37532/0976-0113.14(S1). |
| 2023 | scRNA-Seq Analysis Immunis Mutationes Intratumorales Hapten Plus Chemotherapy Medicamenta ad Sanatio Pectus Cancer Male | ACTA CANCER SCIENTIARUM ET THERAPEUTORUM CLINICALIUM 27 Novembris 2023. DOI:10.26502/jcsct.5079214 |
| 2024 | Effectus sodii stibogluconatus in reficiendis et excitandis cellulis immunibus in fluido pleurae cancere pancreatici praeparatio ad immunotherapyem. | Fines in Immunologia diei 19 Ianuarii 2024. DOI:10.3389/fimmu.2023.1315468 |
| 2024 | Hapten-mediated Chemical Immunis Therapy cum Veneni Administration in Cervical Cancer sine Hysterectomiae | Acta surgery chirurgiae 13 Iunii, 2024. DOI:10.29011/2575-9760.11063 |
| 2024 | Usus scRNA-Seq Profile ad Definire Responsorium immunologicum post Intra-tumorem Hapen Consectatum Chemotherapy in Causa Hemangiopericytomi Hemangiopericytomae intracranialis Hepatis Metastasis: Casus Relatio | Acta chirurgiae chirurgiae 10 Iunii 2024. DOI:10.29011/2575-9760.11063 |
